USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), alanine (unii: of5 - plenamine™ 15% is indicated as an amino acid (nitrogen) source in parenteral nutrition regimens. this use is appropriate when the enteral route is inadvisable, inadequate or not possible, as when: —   gastrointestinal absorption is impaired by obstruction, inflammatory disease or its complications, or antineoplastic therapy; —   bowel rest is needed because of gastrointestinal surgery or its complications such as ileus, fistulae or anastomotic leaks; —   tube feeding methods alone cannot provide adequate nutrition. this solution should not be used in patients in hepatic coma, severe renal failure, metabolic disorders involving impaired nitrogen utilization or hypersensitivity to one or more amino acids.

USA - engelsk - NLM (National Library of Medicine)

icu medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - aminosyn-pf 10%, sulfite-free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with aminosyn-pf 10% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. see dosage and administration for additional information. centr

USA - engelsk - NLM (National Library of Medicine)

icu medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - aminosyn-pf 7%, sulfite-free, (an amino acid injection — pediatric formula) is indicated for the nutritional support of infants (including those of low birth weight) and young children requiring tpn via either central or peripheral infusion routes. parenteral nutrition with aminosyn-pf 7% is indicated to prevent nitrogen and weight loss or treat negative nitrogen balance in infants and young children where (1) the alimentary tract by the oral gastrostomy, or jejunostomy route, cannot or should not be used or adequate protein intake is not feasible by these routes, (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of non-protein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutrition support, and vein tolerance. see dosage and administration for additional information. central

USA - engelsk - NLM (National Library of Medicine)

baxter healthcare corporation - valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), histidine (unii: 4qd397987e) (histidine - unii:4qd397987e), isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), alanine (unii: of5p57n2zx) (alanine - unii:of5p57n2zx), glycine (unii: te7660xo1c) (glycine - unii:te7660xo1c), arginine (unii: 94zla3w45f) (arginine - unii:94zla3w45f), proline (unii: 9dlq4ciu6v) (proline - unii:9dlq4ciu6v), glutamic acid (unii: 3kx376gy7l) (glutamic acid - unii:3kx376gy7l), serine (unii: 452vly9402) (serine - unii:452vly9402), aspartic acid (unii: 30kyc7miai) (aspartic acid - unii:30kyc7miai), tyrosine (unii: 42hk56048u) (tyrosine - unii:42hk56048u) - valine 1.44 g in 100 ml - prosol is indicated as a source of amino acids for patients requiring parenteral nutrition when oral or enteral nutrition is not possible, insufficient, or contraindicated. prosol may be used to treat negative nitrogen balance in patients. the use of prosol is contraindicated in: risk summary limited published data with injectable amino acids solutions, including prosol in pregnant women are not sufficient to inform a drug associated risk for adverse developmental outcomes. however, malnutrition in pregnant women is associated with adverse maternal and fetal outcomes [see clinical considerations]. animal reproduction studies have not been conducted with injectable amino acids solutions, including prosol. the background risk of major birth defects and miscarriage for the indicated population is unknown. all pregnancies have a background risk of birth defect, loss, or other adverse outcomes. however, the background risk in the u.s. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies. clinical considerations disease-associated maternal and/or embryo-fetal risk severe malnutrition in pregnant women is associated with preterm delivery, low birth weight, intrauterine growth restriction, congenital malformations and perinatal mortality. parenteral nutrition should be considered if a pregnant woman’s nutritional requirements cannot be fulfilled by oral or enteral intake. risk summary there are no data available to assess the presence of injectable amino acids, including prosol in human milk, the effects of prosol on the breastfed infant or the effects on milk production. the lack of clinical data during lactation precludes a clear determination of the risk of prosol to a child during lactation; therefore, the developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for prosol and any potential adverse effects on the breastfed child from prosol or from the underlying maternal condition. neonates, especially premature infants with low birth weight, are at increased risk of developing hypo- or hyperglycemia and therefore need close monitoring during treatment with intravenous glucose solutions to ensure adequate glycemic control in order to avoid potential long term adverse effects [see dosage and administration (2.7)]. plasma electrolyte concentrations should be closely monitored in the pediatric patients who may have impaired ability to regulate fluids and electrolytes. hyperammonemia is of special significance in infants (birth to two years). this reaction appears to be related to a deficiency of the urea cycle amino acids of genetic or product origin. it is essential that blood ammonia be measured frequently in infants [see warnings and precautions (5.7)]. because of immature renal function, preterm infants receiving prolonged parenteral nutrition treatment with prosol may be at risk of aluminum toxicity [see warnings and precautions (5.8)]. patients, including pediatric patients, may be at risk for pnald [see warnings and precautions (5.9)]. clinical studies with prosol have not been performed to determine whether subjects aged 65 and over respond differently from other younger subjects. other reported clinical experience has not identified differences in responses between the elderly and younger patients. in general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. in patients with impaired renal function, parenteral nutrition solutions containing prosol should be administered with caution. frequent clinical evaluation and laboratory tests to monitor renal function such as serum electrolytes (especially phosphate and potassium) and fluid balance should be conducted [see dosage and administration (2.6) , and warnings and precautions (5.10)]. in patients with impaired liver function, parenteral nutrition solutions containing prosol should be administered starting at the low end of the dosing range [see dosage and administration (2.5)]. frequent clinical evaluation and laboratory tests to monitor liver function such as bilirubin and liver function parameters should be conducted [see warnings and precautions (5.7) ].

USA - engelsk - NLM (National Library of Medicine)

b. braun medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - isoleucine 0.69 g in 100 ml - parenteral nutrition with 10% freamine® iii (amino acid injection) is indicated to prevent nitrogen loss or treat negative nitrogen balance in adults and pediatric patients where (1) the alimentary tract, by the oral, gastrostomy, or jejunostomy route, cannot or should not be used, or adequate protein intake is not feasible by these routes; (2) gastrointestinal absorption of protein is impaired; or (3) protein requirements are substantially increased as with extensive burns. dosage, route of administration, and concomitant infusion of nonprotein calories are dependent on various factors, such as nutritional and metabolic status of the patient, anticipated duration of parenteral nutritional support, and vein tolerance. see warnings, precautions, pediatric use , and dosage and administration. central venous infusion should be considered when amino acid solutions are to be admixed with hypertonic dextrose to promote protein synthesis in hypercatabolic or severely depleted patients, or those requiring long-term

USA - engelsk - NLM (National Library of Medicine)

hospira, inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - aminosyn ii, sulfite-free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. supplemental electrolytes, in accordance with the prescription of the attending physician, must be added to aminosyn ii solutions without electrolytes. aminosyn ii can be administered peripherally with dilute (5 to 10%) dextrose solution and i.v. fat emulsion as a source of nutritional support. this form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. aminosyn ii is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not

USA - engelsk - NLM (National Library of Medicine)

icu medical inc. - isoleucine (unii: 04y7590d77) (isoleucine - unii:04y7590d77), leucine (unii: gmw67qnf9c) (leucine - unii:gmw67qnf9c), lysine acetate (unii: ttl6g7liwz) (lysine - unii:k3z4f929h6), methionine (unii: ae28f7pnpl) (methionine - unii:ae28f7pnpl), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), threonine (unii: 2zd004190s) (threonine - unii:2zd004190s), tryptophan (unii: 8duh1n11bx) (tryptophan - unii:8duh1n11bx), valine (unii: hg18b9yrs7) (valine - unii:hg18b9yrs7), alanine (unii: of5 - aminosyn ii, sulfite-free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate. supplemental electrolytes, in accordance with the prescription of the attending physician, must be added to aminosyn ii solutions without electrolytes. aminosyn ii can be administered peripherally with dilute (5 to 10%) dextrose solution and i.v. fat emulsion as a source of nutritional support. this form of nutritional support can help to preserve protein and reduce catabolism in stress conditions where oral intake is inadequate. aminosyn ii is also indicated for central vein infusion to prevent or reverse negative nitrogen balance in patients where the alimentary tract, by the oral, gastrostomy or jejunostomy route cannot or should not

USA - engelsk - NLM (National Library of Medicine)

deseret biologicals, inc. - adenosine triphosphate disodium (unii: 5l51b4dr1g) (adenosine triphosphate - unii:8l70q75fxe), asparagine monohydrate (unii: 2pd79vf521) (asparagine - unii:5z33r5tko7), phenylalanine (unii: 47e5o17y3r) (phenylalanine - unii:47e5o17y3r), quercetin (unii: 9ikm0i5t1e) (quercetin - unii:9ikm0i5t1e), sus scrofa ileum (unii: c998r1xsra) (sus scrofa ileum - unii:c998r1xsra), sus scrofa jejunum (unii: ta501qd69r) (sus scrofa jejunum - unii:ta501qd69r), sus scrofa stomach (unii: t0920p9z9a) (sus scrofa stomac - adenosine triphosphate disodium 4 [hp_x] in 1 ml - for the temporary relief of symptoms related to allergies to eggs in foods and supplements, including skin inflammation, hives, runny nose, sneezing, stomach cramps, nausea, vomiting, coughing.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration. for the temporary relief of symptoms related to allergies to eggs in foods and supplements, including skin inflammation, hives, runny nose, sneezing, stomach cramps, nausea, vomiting, coughing.** **these statements are based upon homeopathic principles. they have not been reviewed by the food and drug administration.

Australien - engelsk - APVMA (Australian Pesticides and Veterinary Medicines Authority)

ceva animal health pty ltd - phenylalanine-d - unknown - phenylalanine-d amino acid-phenylalanine-d active 0.0 - active constituent

New Zealand - engelsk - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - alanine 6.3 g/l;  ;  ;  ; arginine 4.1 g/l (l-arginine);  ;  ;  ; aspartic acid 4.1 g/l (l-aspartic acid);  ;  ;  ;  ; cysteine 1 g/l (l-cysteine); glutamic acid 7.1 g/l (l-glutamic acid);  ;  ; glycine 2.1 g/l (as aminoacetic acid);  ; histidine 2.1 g/l (l-histidine);  ;  ; isoleucine 3.1 g/l (l-isoleucine);  ;  ;  ; leucine 7 g/l (l-leucine);  ;  ;  ; lysine monohydrate 5.6 g/l (l-lysine as monohydrate); methionine 1.3 g/l (l-methionine);  ; phenylalanine 2.7 g/l (l-phenylalanine);  ;  ;  ;  ;  ; proline 5.6 g/l (l-proline);  ;  ; serine 3.8 g/l (l-serine);  ;  ;  ;  ; taurine 300 mg/l;  ;  ; threonine 3.6 g/l (l-threonine);  ;  ;  ; tryptophan 1.4 g/l (l-tryptophan);  ;  ;  ; tyrosine 500 mg/l (l-tyrosine); valine 3.6 g/l (l-valine);  ;  ;   - solution for infusion - active: alanine 6.3 g/l       arginine 4.1 g/l (l-arginine)       aspartic acid 4.1 g/l (l-aspartic acid)         cysteine 1 g/l (l-cysteine) glutamic acid 7.1 g/l (l-glutamic acid)     glycine 2.1 g/l (as aminoacetic acid)   histidine 2.1 g/l (l-histidine)     isoleucine 3.1 g/l (l-isoleucine)       leucine 7 g/l (l-leucine)       lysine monohydrate 5.6 g/l (l-lysine as monohydrate) methionine 1.3 g/l (l-methionine)   phenylalanine 2.7 g/l (l-phenylalanine)           proline 5.6 g/l (l-proline)     serine 3.8 g/l (l-serine)         taurine 300 mg/l     threonine 3.6 g/l (l-threonine)       tryptophan 1.4 g/l (l-tryptophan)       tyrosine 500 mg/l (l-tyrosine) valine 3.6 g/l (l-valine)       excipient: water for injection - vaminolact is indicated as a source of amino acids in children needing intravenous nutrition.